The worlds leading developer of proton therapy centres


Rutherford Health plc is a UK incorporated holding company of a group at the vanguard of advancing cancer care in the UK and internationally, building a network of oncology centres known as the Rutherford Cancer Centres, committed to providing innovative cancer care of the highest quality.

We have partnered with leading providers to equip each centre with the very latest cancer technology, including IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions, Elekta, a leading provider of radiotherapy treatments, and Philips, a leader in health technology. Each Rutherford centre offers a comprehensive range of cancer treatments to patients including proton therapy, radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and wellbeing services.

We plan to open further centres over the next few years and our first centre in South Wales was the first in the UK to offer and treat with high energy proton beam therapy in April 2018. As well as the Rutherford Cancer Centre South Wales, two further centres have opened – the Rutherford Cancer Centre North East in Northumberland and the Rutherford Cancer Centre Thames Valley in Reading, with both already delivering conventional radiotherapy and chemotherapy treatments, with proton therapy now available in both in 2019. A fourth site is under construction in Liverpool, the Rutherford Cancer Centre North West, which is due to be completed in 2020.

The Company was established in February 2015 with the establishment of Rutherford Health plc (formerly known as Proton Partners International Limited) by the Company’s Chief Executive Officer, Mike Moran MBE and its Chief Medical Officer, Professor Edward Karol Sikora, in order to challenge conventional thinking on how best to provide leading edge cancer treatment to patients in the UK including proton therapy which was previously only available outside the UK.

We are also revolutionising the future of healthcare more widely - Rutherford Estates is disrupting healthcare construction through rapid delivery of state-of-the-art oncolgy centres, Rutherford Innovations is advancing cancer research and leading the way in research & development focussed on proton therapy, and Rutherford Diagnostics is going to transform medical diagnostics and genomic sequencing by providing access to all for rapid diagnostic services.